Cargando…

Morphological and molecular characteristics of HER2 amplified urothelial bladder cancer

Several (pre-) clinical trials are currently investigating the benefit of HER2-targeted therapy in urothelial bladder cancer (UBC). Patients with HER2 amplified UBC could potentially profit from these therapies. However, little is known about histomorphology, HER2 protein expression patterns and occ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tschui, J., Vassella, E., Bandi, N., Baumgartner, U., Genitsch, V., Rotzer, D., Seiler, R., Thalmann, G. N., Fleischmann, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4460277/ https://www.ncbi.nlm.nih.gov/pubmed/25809292 http://dx.doi.org/10.1007/s00428-015-1729-4

Ejemplares similares

Her2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapy
por: Kiss, Bernhard, et al.
Publicado: (2017)

Pelvic lymph nodes: distribution and nodal tumour burden of urothelial bladder cancer
por: Seiler, Roland, et al.
Publicado: (2010)

Evolution of Urothelial Bladder Cancer in the Context of Molecular Classifications
por: Minoli, Martina, et al.
Publicado: (2020)

Neuroendocrine Differentiation in Metastatic Conventional Prostate Cancer Is Significantly Increased in Lymph Node Metastases Compared to the Primary Tumors
por: Genitsch, Vera, et al.
Publicado: (2017)

Characteristics of upper urinary tract urothelial carcinoma in the context of bladder cancer: a narrative review
por: Giudici, Nicola, et al.
Publicado: (2021)

Immune Profiling Reveals Molecular Classification and Characteristic in Urothelial Bladder Cancer
por: Yang, Li, et al.
Publicado: (2021)

Molecular classification of urothelial bladder carcinoma
por: Schwarzova, Lucia, et al.
Publicado: (2023)

Survivin and Her2 Expressions in Different Grades of Urothelial Neoplasms of Urinary Bladder
por: Moradi Tabriz, Hedieh, et al.
Publicado: (2021)

Correlation of HER2 With p53 and p63 in Urothelial Bladder Carcinoma
por: Ponnaboina, Divya Madhuri, et al.
Publicado: (2023)

miR-34a and miR-15a/16 are co-regulated in non-small cell lung cancer and control cell cycle progression in a synergistic and Rb-dependent manner
por: Bandi, Nora, et al.
Publicado: (2011)

Clinical and molecular characterization of HER2 amplified-pancreatic cancer
por: Chou, Angela, et al.
Publicado: (2013)

HER2 Protein Overexpression and Gene Amplification in Plasmacytoid Urothelial Carcinoma of the Urinary Bladder
por: Kim, Bohyun, et al.
Publicado: (2016)

Progress in the Research and Targeted Therapy of ErbB/HER Receptors in Urothelial Bladder Cancer
por: Chen, Dong, et al.
Publicado: (2021)

Comprehensive molecular characterization of urothelial bladder carcinoma
Publicado: (2014)

HER-3 expression in HER-2-amplified breast carcinoma
por: Czopek, Jacek, et al.
Publicado: (2013)

Bladder cancer organoids as a functional system to model different disease stages and therapy response
por: Minoli, Martina, et al.
Publicado: (2023)

Identification and validation of molecular subtypes’ characteristics in bladder urothelial carcinoma based on autophagy-dependent ferroptosis
por: Liu, Shiwei, et al.
Publicado: (2023)

Characteristics of the immunogenicity and tumor immune microenvironment in HER2-amplified lung adenocarcinoma
por: Wang, Qinyang, et al.
Publicado: (2022)

Status of Her2 over expression in muscle invasive urothelial bladder carcinoma: Report of 21 cases
por: Mejri, Nesrine, et al.
Publicado: (2014)

Clinical Significance of Substaging and HER2 Expression in Papillary Nonmuscle Invasive Urothelial Cancers of the Urinary Bladder
por: Lim, So Dug, et al.
Publicado: (2015)

Evaluation of the Expression of HER2 and c-KIT Proteins as Prognostic Markers in Superficial Bladder Urothelial Carcinoma
por: Abdou Hassan, Wael, et al.
Publicado: (2021)

Molecular Characterization of Urothelial Carcinoma of the Bladder and Upper Urinary Tract
por: Lee, Ji Yun, et al.
Publicado: (2017)

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
por: Majumder, Avisek, et al.
Publicado: (2021)

Molecular and Morphological Characteristics of the De-Obstructed Rat Urinary Bladder—An Update
por: Uvelius, Bengt, et al.
Publicado: (2022)

HER2 Expression Associated with Clinical Characteristics and Prognosis of Urothelial Carcinoma in a Chinese Population
por: Zhou, Li, et al.
Publicado: (2023)

New therapeutic targets in the management of urothelial carcinoma of the bladder
por: Sverrisson, Einar F, et al.
Publicado: (2013)

Evidence for Bladder Urothelial Pathophysiology in Functional Bladder Disorders
por: Keay, Susan K., et al.
Publicado: (2014)

The clinicopathological characteristics of muscle‐invasive bladder recurrence in upper tract urothelial carcinoma
por: Shigeta, Keisuke, et al.
Publicado: (2021)

Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers
por: Campbell, Marcia R., et al.
Publicado: (2022)

HER2 as a target in invasive urothelial carcinoma
por: Bellmunt, Joaquim, et al.
Publicado: (2015)

HER2 and EGFR amplification and expression in urothelial carcinoma occurs in distinct biological and molecular contexts
por: Eriksson, Pontus, et al.
Publicado: (2017)

Distinctive morphological and molecular features of urothelial carcinoma with an inverted growth pattern
por: Sanguedolce, Francesca, et al.
Publicado: (2021)

Intravesical therapy for urothelial carcinoma of the bladder
por: Manoharan, M.
Publicado: (2011)

Urothelial Bladder Cancer Urinary Biomarkers
por: Noon, Aidan P, et al.
Publicado: (2014)

Role of angiogenesis in urothelial bladder carcinoma
por: Fus, Łukasz Piotr, et al.
Publicado: (2016)

Bladder melanosis with concurrent urothelial carcinoma
por: Yau, Susanna E., et al.
Publicado: (2017)

Cutaneous metastasis of bladder urothelial carcinoma
por: Hasan, Osamah, et al.
Publicado: (2019)

Giant Cell Urothelial Carcinoma of Bladder
por: Wijesinghe, Harshima Disvini, et al.
Publicado: (2021)

Differential Expression and Clinicopathological Significance of HER2, Indoleamine 2,3-Dioxygenase and PD-L1 in Urothelial Carcinoma of the Bladder
por: Kim, Donghyun, et al.
Publicado: (2020)

Molecular targets in urothelial cancer: detection, treatment, and animal models of bladder cancer
por: Smolensky, Dmitriy, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_g2h9dsu7uv5lk8oo49m4c44i7q